物理性质
- 熔点-108 °C
- 沸点72.8±3.0 °C at 760 mmHg
- 闪点21.1±10.7 °C
- 密度1.9±0.1 g/cm3
- PSA:0.0
- LogP:2.03
- 折射率1.516
- 蒸汽压127.8±0.1 mmHg at 25°C
- 溶解性4g/l(缓慢分解)
- 敏感性1.稳定性 稳定2.禁配物 强氧化剂、强碱3.避免接触的条件 受热、光照、接触空气4.聚合危害 不聚合5.分解产物 碘化氢
- 外观形态无色至黄色液体
- 储存条件1.以25~500ml玻璃瓶装,外用木箱或纸箱保护。贮存于阴凉、干燥环境、通风的库房中,远离火种、热源,避光保存。不得与食用化工原料混放。
2.储存注意事项储存于阴凉、通风的库房。远离火种、热源。避免光照。包装要求密封保存,不可与空气接触。应与氧化剂、碱类、食用化学品分开存放,切忌混储。配备相应品种和数量的消防器材。储区应备有泄漏应急处理设备和合适的收容材料。
- 产品应用用于医药,有机合成.
- 性质描述无色至淡黄色液体.久置变红.熔点-108°C,沸点72°C,相对密度1.9358(20/4°C),折光率1.5133,折射率1.5130.溶于乙醇,乙醚,能与大多数有机溶剂混溶,微溶于水并逐渐分解.高热下分解出有毒烟气(碘化物),遇水和蒸汽能产生有毒有腐蚀性烟气.与氧化剂能发生剧烈反应,遇明火能燃烧.
MSDS等安全信息
- GHS象形图


- GHS符号GHS07 & GHS08;
注释: Exclamation mark & Health hazard - 危险类别急性毒性 类别4(经口)
特定目标器官毒性 - 单次接触 类别3
皮肤腐蚀/刺激 类别2
严重眼刺激 类别2
呼吸道致敏 类别1
皮肤致敏 类别1
皮肤致敏 类别1B
易燃液体 类别3
急性毒性 类别4(吸入)
急性毒性 类别4(经皮)
致突变性 类别2
严重眼损伤 类别1
易燃液体 类别4
严重眼刺激 类别2A
严重眼刺激 类别2B
STOT SE 2 - 警示词Danger(危险)
- 危险描述H302 |吞咽有害.
H335 |可能引起呼吸道刺激.
H315 |造成皮肤刺激.
H319 |造成严重眼刺激.
H334 |吸入可能引起过敏或哮喘症状或呼吸困难.
H317 |可能引起皮肤过敏反应.
H226 |易燃液体和蒸气.
H332 |吸入有害.
H312 |皮肤接触有害.
H341 |怀疑导致遗传缺陷.
H318 |造成严重眼损伤.
H227 |可燃液体
H371 |可能损害器官. - 防范说明P203, P210, P233, P240, P241, P242, P243, P260, P261, P264, P264+P265, P270, P271, P272, P280, P284, P301+P317, P302+P352, P303+P361+P353, P304+P340, P305+P351+P338, P317, P318, P319, P321, P330, P332+P317, P333+P317, P337+P317, P342+P316, P362+P364, P370+P378, P403, P403+P233, P403+P235, P405, and P501
- UN编号2922
- 危险品标志Xn:Harmful
- 安全声明S23-S26-S36/37-S45-S37/39-S16
- 危险类别码R10,R36/37/38,R20
- WGK Germany3
欧盟法规
REACH注册ECHA物质C&L通报REACH预注册上下游产品
CAS号64-17-5 乙醇 | CAS号107-25-5 乙烯基甲醚 | CAS号107-19-7 丙炔醇 | CAS号2031-67-6 三乙氧基甲基硅烷 | CAS号932-92-3 Cyclohexane, ethoxy | CAS号78371-07-0 (3S,5S,8R,9S,10... | CAS号77067-57-3 4-ethoxy°Ctane | CAS号45817-37-6 1-ethenyl-4-(io... | CAS号122-52-1 亚磷酸三乙酯 | CAS号104746-44-3 triethyltellani... | CAS号106039-67-2 (9ci)-2-(乙基硫代)-... | CAS号111562-23-3 1-ethyl-1-[2-[2... | CAS号111915-74-3 ethyl N'-prop-2... | CAS号108266-28-0 1-Menthoxy-1-butyne | CAS号110700-49-7 齐墩果酸乙酯 | CAS号1113-04-8 ethyl-(2-hydrox... | CAS号108373-05-3 3-溴-4-乙氧基苯甲醛 | CAS号111414-36-9 4-ethyl-4-[2-[2... | CAS号104664-40-6 2-[5,6-diethyl-...硫酸二乙酯置于alkaline Earth Iodide,水体系中,化学反应生成 碘乙烷
参考文献:De175209
标题:De175209
专利信息
专利号:WO-2019170521-A1
优先权日:2018-03-07
标题 :Synthesis of obeticholic acid and synthesis intermediate
发明人:BERNABEU MARTÃ?NEZ MARÃ?A DEL CARMEN; JIMÉNEZ ALONSO OSCAR; DOBARRO RODRÃ?GUEZ ALICIA; GABOARDI MAURO; CASTALDI GRAZIANO
权利人:MOEHS IBERICA SL
摘要:The present invention relates to a new intermediate for the synthesis of obeticholic acid, the compound of formula (I) or a geometric isomer thereof, a process for obtaining the same, as well as the use of said intermediate in the synthesis of obeticholic acid.
专利号:US-6376676-B1
优先权日:1993-06-30
标题 :Intermediates in the synthesis of (±)-camptothecin and related compounds and synthesis thereof
发明人:CURRAN DENNIS P; LIU HUI
权利人:UNIV PITTSBURGH
摘要:The present invention provides a short, convergent total synthesis of novel intermediates in the synthesis of (±)-camptothecin and related compounds. The present synthesis scheme includes a novel 4+1 radical annulation followed by another cyclization to simultaneously assemble rings B and C of the camptothecin compound. The present invention also provides novel chemical intermediates for such 4+1 radical annulations.
专利号:US-6252079-B1
优先权日:1993-06-30
标 题 :Intermediates in the synthesis of camptothecin and related compounds and synthesis thereof
发明人:CURRAN DENNIS P; BOM DAVID
权利人:UNIV PITTSBURGH
摘要:The present invention provides a short, convergent total synthesis of irinotecan and derivative compounds which comprises of a novel 4+1 radical annulation wherein the precursoris reacted with an aryl isonitrile having the formulawherein X is Br or I, and R4 is an alkyl group, an allyl group, a propargyl group or a benzyl group, and R16 is H, a C1-C6 alkoxy group, agroup wherein p is an integer between 4 and 12, or a C1-C12 acyclic dialkylamino group. The present invention also provides novel chemical intermediates for such 4+1 radical annulations.
专利号:WO-9517903-A1
优先权日:1993-12-28
标 题:Modular design and synthesis of oxazolone-derived molecules
发明人:HOGAN JOSEPH C JR; CASEBIER DAVID; FURTH PAUL; TU CHENG
权利人:ARQULE PARTNERS L P; HOGAN JOSEPH C JR; CASEBIER DAVID; FURTH PAUL; TU CHENG
摘要:The design and synthesis of novel oxazolone-derived molecular modules and the use of the modules in the construction of new molecules and fabricated materials is disclosed. The new molecules and fabricated materials are molecular recognition agents useful in the design and synthesis of drugs, and have applications in separations and materials science.
专利号:US-4459420-A
优先权日:1982-05-17
标题 :Pyrogallol synthesis of anti-atherogenic furochromones
发明人:GAMMILL RONALD B
权利人:UPJOHN CO
摘要:The present invention provides a total synthesis of known intermediates useful in the synthesis of khellin and antiatherosclerotic analogs thereof from pyrogallol. Pyrogallol is converted to 3,6,7-benzofurantriol triacetate using zinc chloride and chloracetanitrile, then catalytically reduced and deactoxylated at the 3 position to yield the corresponding 2,3-dihydrofuran. This substance is subjected to a Fries rearrangement to the corresponding diol, the phenolic hydroxyl group of which is then selectively alkylated. This yields 6-hydroxy-7-alkoxy-5-benzofuranyl methyl ketone, a known intermediate for the production of 4-desmethoxy khellin and analogs thereof. This compound is then selectively alkoxylated at the 4 position using lead tetraacetate or thallium (III) nitrate in an alkanol solvent to yield known chemical intermediates in the preparation of khellin and analogs thereof.
专利号:US-11999757-B2
优先权日:2017-11-01
标 题:Synthesis of boronate ester derivatives and uses thereof
发明人:BOYER SERGE HENRI; HECKER SCOTT J; VERZIJL GERARDUS K M; HERMSEN PETRUS J
权利人:MELINTA SUBSIDIARY CORP
摘要:Disclosed herein are methods for the preparation of boronate derivatives in the synthesis of antimicrobial compounds and uses thereof. Disclosed herein includes method of making a compound of Formula (B) by reducing the ketone group of the keto-ester compound of Formula (A), and the reduction can be performed using a Ruthenium based catalyst system or using an alcohol dehydrogenase bioreduction system.